Ra Pharmaceuticals Inc (RARX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ra Pharmaceuticals Inc (RARX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9957
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide chemistry platform. Its lead product candidate, RA101495 is a self-administered subcutaneous (SC) injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharmaceuticals pipeline also includes RA101495, an administered SC, to treat debilitating complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and lupus nephritis (LN). The company also carries out various preclinical programs intended for the treatment of orphan renal diseases, ocular, autoimmune and CNS diseases; and a non-complement cardiovascular product candidate. Ra Pharmaceuticals is headquartered on Cambridge, Massachusetts, the US.

Ra Pharmaceuticals Inc (RARX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 14
Licensing Agreements 15
Merck Enters into Licensing Agreement with Ra Pharma 15
Equity Offering 17
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 17
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 18
Ra Pharma Prices IPO for USD91 Million 20
Ra Pharmaceuticals Inc – Key Competitors 22
Ra Pharmaceuticals Inc – Key Employees 23
Ra Pharmaceuticals Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 08, 2018: Ra Pharmaceuticals reports second quarter 2018 financial results 25
May 09, 2018: Ra Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 26
Mar 14, 2018: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 28
Nov 09, 2017: Ra Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 30
Aug 09, 2017: Ra Pharmaceuticals Reports Second Quarter 2017 Financial Results 31
May 11, 2017: Ra Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 33
Mar 06, 2017: Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 34
Corporate Communications 36
Sep 25, 2018: Ra Pharma names Aoife M. Brennan, M.B., B.Ch., to Board of Directors 36
Apr 18, 2018: Ra Pharmaceuticals Names John C. King as Chief Commercial Officer 37
Government and Public Interest 38
Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 38
Product News 39
06/24/2017: Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association 39
05/18/2017: Ra Pharmaceuticals to Present at the 22nd Congress of the European Hematology Association 40
Product Approvals 41
Jul 31, 2017: Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for RA101495 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria 41
Clinical Trials 42
Sep 28, 2018: Ra Pharma reports positive data from Phase lb trial of zilucoplan 42
Sep 05, 2018: Ra Pharma Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Phase 3 PNH Program 43
Aug 08, 2018: Ra Pharmaceuticals announces early completion of enrollment in gMG Phase 2 program 44
May 17, 2018: Ra Pharmaceuticals to Present at the 23rd Congress of the European Hematology Association 46
Feb 12, 2018: Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria 47
Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment 49
Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients 50
Dec 04, 2017: Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria 51
Jul 19, 2017: Ra Pharmaceuticals Announces Publication of Positive Preclinical Data with RA101295 for the Treatment of Escherichia Coli Sepsis 53
Jun 27, 2017: Ra Pharmaceuticals Announces Initial Data from Phase 2 Clinical Trial of RA101495 in PNH 54
Jun 21, 2017: Ra Pharmaceuticals to Host Conference Call on Initial Phase 2 Data for RA101495 in PNH 55
Apr 26, 2017: Ra Pharmaceuticals Initiates Dosing of RA101495 in PNH Patients 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Ra Pharma Raises USD58.5 Million in Series B Financing 12
Ra Pharma Raises US$8.6 Million In Second Tranche Of Series A Financing 14
Merck Enters into Licensing Agreement with Ra Pharma 15
Ra Pharma Plans to Raise up to USD50 Million in Public Offering of Shares 17
Ra Pharma Prices Public Offering of Shares for USD50.4 Million 18
Ra Pharma Prices IPO for USD91 Million 20
Ra Pharmaceuticals Inc, Key Competitors 22
Ra Pharmaceuticals Inc, Key Employees 23

List of Figures
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ra Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ra Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Ra Pharmaceuticals Inc (RARX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Antibe Therapeutics Inc (ATE):企業の財務・戦略的SWOT分析
    Summary Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen deriv …
  • Oncolix Inc-製薬・医療分野:企業M&A・提携分析
    Summary Oncolix Inc (Oncolix) is a clinical stage biopharmaceutical company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor …
  • Tarsus Group Plc:企業のM&A・事業提携・投資動向
    Tarsus Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tarsus Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • China Eastern Airlines Corporation Limited:企業の戦略・SWOT・財務情報
    China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary China Eastern Airlines Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Shelby Energy Cooperative, Inc.:企業の戦略的SWOT分析
    Shelby Energy Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Principia Biopharma Inc (PRNB):製薬・医療:M&Aディール及び事業提携情報
    Summary Principia Biopharma Inc (Principia Biopharma) is a clinical stage biopharmaceutical company that designs and develops oral small molecule drug therapies for immune disorders and cancer. The company, through its proprietary Tailored Covalency platform, develops a portfolio of drug candidates …
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Groupama Assurances Mutuelles:企業の戦略・SWOT・財務分析
    Groupama Assurances Mutuelles - Strategy, SWOT and Corporate Finance Report Summary Groupama Assurances Mutuelles - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • BioTime Inc (BTX):製薬・医療:M&Aディール及び事業提携情報
    Summary BioTime Inc (BioTime) is a biotechnology company which focuses on regenerative medicine and plasma volume expanders. The company’s Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. It is also develo …
  • Hitachi Zosen Corp (7004):電力:M&Aディール及び事業提携情報
    Summary Hitachi Zosen Corp (Hitz) is an industrial and engineering company. It designs, constructs and operates refuse incineration and recycling facilities, pressure vessels, marine diesel engines, and press machines, and other process machine. The company also provides after-sales servicing and ma …
  • Skechers U.S.A., Inc. (SKX):企業の財務・戦略的SWOT分析
    Skechers U.S.A., Inc. (SKX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Rocky Mountain Chocolate Factory, Inc.:企業の戦略・SWOT・財務分析
    Rocky Mountain Chocolate Factory, Inc. - Strategy, SWOT and Corporate Finance Report Summary Rocky Mountain Chocolate Factory, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • High Arctic Energy Services Inc (HWO):企業の財務・戦略的SWOT分析
    Summary High Arctic Energy Services Inc (High Arctic) operates as an oil and gas company that provides drilling services and equipment for rentals. The company provides services such as drilling services, matting and equipment rentals, snubbing services and nitrogen services. It offers equipment ren …
  • China Huaneng Group:発電所・企業SWOT分析
    China Huaneng Group - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Rabigh Refining & Petrochemical Co (2380):企業の財務・戦略的SWOT分析
    Rabigh Refining & Petrochemical Co (2380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Nymox Pharmaceutical Corp (NYMX):企業の財務・戦略的SWOT分析
    Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Korea East-West Power Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Korea East-West Power Co., Ltd. (EWP), subsidiary of Korea Electric Power Corporation, is a state-owned electric utility that generates and supplies electricity. It produces electricity from various sources including coal, oil, liquefied natural gas, mini hydro, and renewable sources such as …
  • Aeon Delight Co Ltd:企業の戦略・SWOT・財務情報
    Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Suzhou Xinrong Best Medical Instrument Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Suzhou Xinrong Best Medical Instrument Co Ltd (Suzhou Xinrong) is a medical device company that manufactures orthopedic medical instruments. The company prvides products such as medullary cavity plug, acetabular screws, metal ball head, stem and titanium plate anterior thoracolumbar fixed eq …
  • RegenxBio Inc (RGNX):製薬・医療:M&Aディール及び事業提携情報
    Summary RegenxBio Inc (RegenxBio), formerly ReGenX Biosciences LLC is a provider of therapeutics for various diseases. The company develops, commercializes and licenses recombinant adeno-associated virus (AAV) gene therapy. Its products include AAV plasmids, AAV vector reporter systems and custom AA …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆